AI stocks have been on fire in 2025. After Oracle and other hyperscalers revealed record-breaking capital expenditures, most semiconductor names raced back toward all-time highs. Yet one company that sits at the very heart of chip production has been noticeably absent from the party, ASML.
Despite that enviable position, the stock hasn’t kept pace with the AI rally.
When an apparel brand starts showing signs of stress, sales sliding, margins crumbling, losses mounting, the Street doesn’t hesitate to slap the “dying business” label on it.
That’s why it might surprise some investors that Lululemon doesn’t actually fit that description right now. In Q2, sales rose, margins held within historical ranges, and earnings only marginally dipped.
» Read more about: Is Lululemon Losing Its Shine, or Just Catching Its Breath? »
Chime Financial is one of the most talked-about fintech players, but it has had a rollercoaster ride since its June IPO. The stock ran up to $43 on its first day of trading, riding a wave of excitement around digital banking. Fast-forward to today, and shares have been clipped by almost 50%.
So the big question is can Chime regain momentum and reward patient investors?
Every once in a while, a company comes along that feels like the rare exception, a business so well-positioned, diversified, and forward-looking that it could anchor a portfolio for years.
Broadcom is one of those companies and it might be the single best position to hold for the foreseeable future.
Broadcom combines cyclical chip sales with high-margin recurring software revenue from acquisitions like CA,
Eli Lilly has been a frustrating hold so far this year. Shares are slightly down year to date, a rare stumble for a company that has delivered nearly 5x returns over the past five years.
For a stock that’s become a poster child of the weight-loss and diabetes boom, the slowdown in momentum has left investors wondering if the story has run its course.
It didn’t take long for Figma to go from Wall Street’s darling to one of its biggest disappointments.
After a blockbuster debut this summer, the stock has been sliding steadily, leaving many early investors deep in the red. But is the sell-off a warning sign, or has the market simply overreacted?
Figma grew revenue 41% year over year and turned a $178 million cash burn into $62.5 million in positive operating cash flow,
» Read more about: Is Figma’s Stock a Falling Knife or a Hidden Bargain? »
With a market cap north of $2.2 trillion, more than half the value of every cryptocurrency combined, Bitcoin is a financial phenomenon.
But one of its most outspoken champions, Strategy co-founder Michael Saylor, doesn’t think Bitcoin’s story has even started. In fact, his latest forecast makes today’s price tag look like pocket change.
» Read more about: Why Bitcoin’s Path to $1 Million May Be More Realistic Than You Think »
Alphabet (NASDAQ: GOOGL) is already a giant, but it may still be in the early innings of its growth story. With a market capitalization hovering just shy of $3 trillion, it is within striking distance of becoming the world’s next $4 trillion stock.
What makes this more than just speculation is that several potential roadblocks have recently cleared,
» Read more about: Could Alphabet Become the World’s Largest Company »
Billionaires tend to be especially skilled at spotting seismic shifts in industries before the crowd catches on. Recently, one stock has managed to capture the imagination of both a cautious billionaire and aggressive hedge fund managers alike, a company that sits at the very heart of artificial intelligence Nvidia.
David Tepper dramatically increased their Nvidia stakes,
» Read more about: Should You Follow This Billionaire Into Nvidia? »
Dentsply Sirona (NASDAQ: XRAY), one of the world’s largest makers of dental equipment and supplies, was created in 2016 when Dentsply merged with Sirona Dental Systems.
Fast forward to today, and the company is battling falling sales, mounting losses, and a stock price that has been hammered by more than 44% in the past year.
» Read more about: Is This Dental Stock a Stunning Bargain? »
